Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0461929603
Thu, 16.02.2023
Xlife Sciences AG
Medical Screening Device Set to Measure Complex Neurocognitive Performance for Early Detection of Severe Neurodegenerative Diseases Such as Parkinson's or Alzheimer's
saniva diagnostics, a portfolio company of Xlife Sciences (SIX: XLS), has received the 513(g) approval from the US Food and Drug Administration (FDA) to market and sell its proprietar [ … ]
Mon, 23.01.2023
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Stifel initiates research coverage of Xlife Sciences
23.01.2023 / 07:00 CET/CEST
The renowned investment bank Stifel commenced its research coverage of Xife Sciences (SIX: XLS). The corresponding initial analyst report rates Xlife Sciences' stock with a “Buy” rating and calls for [ … ]
Fri, 20.01.2023
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Patent
Xlife Sciences: Swiss portfolio company Axenoll receives strategically significant patent by the European Patent OfficeTitle
20.01.2023 / 07:00 CET/CEST
Xlife Sciences AG (SIX: XLS) announced today that its Swiss portfolio company Axenoll Life Sciences AG has been granted a strategically si [ … ]
Mon, 16.01.2023
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Xlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS)
16.01.2023 / 07:00 CET/CEST
Xlife Sciences' (SIX: XLS) portfolio company inflamed pharma has launched a research project to develop a potential therapy for amyotr [ … ]
Thu, 01.12.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies 01.12.2022 / 07:01 CET/CEST
Lysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Sciences and curasan (a l [ … ]
Thu, 01.12.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies 01.12.2022 / 07:01 CET/CEST
Lysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Sciences and curasan (a l [ … ]
Mon, 28.11.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
alytas therapeutics collaborates with spin-off from the German Diabetes Center
28.11.2022 / 07:00 CET/CEST
Xlife Sciences’ (SIX: XLS) portfolio company alytas therapeutics (located in Jena, Germany) explores innovative, antibody-based therapeutic concepts for treatment of morbid obes [ … ]
Mon, 28.11.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
alytas therapeutics collaborates with spin-off from the German Diabetes Center
28.11.2022 / 07:00 CET/CEST
Xlife Sciences’ (SIX: XLS) portfolio company alytas therapeutics (located in Jena, Germany) explores innovative, antibody-based therapeutic concepts for treatment of morbid obes [ … ]
Mon, 21.11.2022
Xlife Sciences AG
The Board of Directors of Xlife Sciences AG (SIX: XLS), a leading European life sciences incubator and accelerator based in Switzerland, has initiated a process to review strategic options, aimed at accelerating the company's business development, and increasing value for its stakeholders. This review will consider all options available to the comp [ … ]
Mon, 21.11.2022
Xlife Sciences AG
The Board of Directors of Xlife Sciences AG (SIX: XLS), a leading European life sciences incubator and accelerator based in Switzerland, has initiated a process to review strategic options, aimed at accelerating the company's business development, and increasing value for its stakeholders. This review will consider all options available to the comp [ … ]